In breast cancer, the PI3K–AKT–mTOR pathway is often activated by genomic abnormalities, most commonly by PIK3CA hotspot mutations, PTEN copy number loss, or activation of upstream signaling cues derived from receptor tyrosine kinases (Ciriello et al., 2015; Mukohara, 2015). Here, PIK3CA is linked to breast cancer.